# Dementia Discovery Fund

> Dementia Discovery Fund is a VC fund backing Biotechnology and Health Care. See 53 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 53
- Last investment: Jun 2026
- Lead investor: 40%
- Fund size: $337M
- Last fund: Mar 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/dementia-discovery-fund/
- X (Twitter): https://twitter.com/theddfund
- Website: https://svhealthinvestors.com/

Dementia Discovery Fund is a VC fund in London focused on Biotechnology and Health Care. The Dementia Discovery Fund is the world’s largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease.The DDF has raised a total of £250 million to develop novel disease-modifying therapeutics for all forms of dementia.They have a mandate to validate novel hypotheses andexpand the breadth of targets and mechanisms in development for dementia over the 15 year life of the fund.This enables the DDF to invest in truly novel, early-stage projects starting from target identification, and explore novel biological insights for translation into disease-modifying drugs.

## Contacts

5 contacts available for Dementia Discovery Fund. Shizune tracks 9 team members at Dementia Discovery Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/dementia-discovery?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $5.8M–$20M |
| Series A | $7M–$78M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 21 | 40% |
| Health Care | 13 | 25% |
| Therapeutics | 13 | 25% |
| Medical | 8 | 15% |
| Life Science | 6 | 11% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 12 | 23% |
| Series A | 12 | 23% |
| Funding Round | 7 | 13% |
| Series B | 5 | 9% |
| Series C | 1 | 2% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 17 | 32% |
| United Kingdom | 11 | 21% |
| Israel | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Angus Grant | Chief Executive Officer | 0 | https://shizune.co/investors/profile/angus-grant |
| Barbara Tate | Chief Strategy Officer | 0 | https://shizune.co/investors/profile/barbara-tate |
| Jonathan Behr | Partner | 9 | https://shizune.co/investors/profile/jonathan-behr-2 |
| Jonathan Behr | Partner | 0 | https://shizune.co/investors/profile/jonathan-behr-1cb6 |
| Damian Crowther | Entrepreneur In Residence | 0 | https://shizune.co/investors/profile/damian-crowther |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M | Seed | Jun 23, 2026 |  |
| Violet Therapeutics | Violet Therapeutics is a healthcare company that operates in stealth mode. | $4.8M | Seed | May 13, 2026 |  |
| Cerevance | Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, thecompany generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. | $20M | Series C | May 12, 2026 |  |
| Endlyz Therapeutics | ndLyz Therapeutics, Inc. is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias. | $17.3M | Seed | Apr 23, 2026 |  |
| NRG Therapeutics | NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M | Series B | Sep 08, 2025 |  |
| Leal Therapeutics | Leal Therapeutics develops novel therapeutics for patients. | $30M | Series A | Aug 27, 2025 |  |
| Therini Bio | Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation. | $39M | Series A | May 14, 2025 |  |
| Montara Therapeutics | Montara Therapeutics is a biotechnology company. | $20M | Seed | Mar 13, 2025 |  |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $31M | Seed | Mar 05, 2025 |  |
| Harness Therapeutics | Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. |  |  | Jan 27, 2025 |  |

10 of 53 investments shown.

## Co-investors
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 11 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 10 deals together
- [MRL Ventures Fund](https://shizune.co/investors/profile/mrl-venture-fund) — VC Fund, 8 deals together
- [AbbVie Biotech Ventures](https://shizune.co/investors/profile/abbvie-biotech-ventures) — VC Fund, 7 deals together
- [MP Healthcare Venture Management](https://shizune.co/investors/profile/mp-healthcare-venture-management-inc) — VC Fund, 7 deals together
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Biotech Investors in United Kingdom](https://shizune.co/investors/biotech-investors-united-kingdom)
- [Biotech VC Funds in United Kingdom](https://shizune.co/investors/biotech-vc-funds-united-kingdom)
- [Life Science Investors](https://shizune.co/investors/life-science-investors)
- [Life Science VC Funds](https://shizune.co/investors/life-science-vc-funds)
- [Life Science Investors in United Kingdom](https://shizune.co/investors/life-science-investors-united-kingdom)
- [Life Science VC Funds in United Kingdom](https://shizune.co/investors/life-science-vc-funds-united-kingdom)

## FAQ

### What does Dementia Discovery Fund invest in?

Dementia Discovery Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 53 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Dementia Discovery Fund's check size?

Dementia Discovery Fund typically joins rounds of $5.8M–$20M at Seed and $7M–$78M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Dementia Discovery Fund participates in.

### How do I contact Dementia Discovery Fund?

Public channels for Dementia Discovery Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Dementia Discovery Fund?

The team at Dementia Discovery Fund includes Angus Grant (Chief Executive Officer), Barbara Tate (Chief Strategy Officer) and Jonathan Behr (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co